Actively Recruiting
Comparison of Multi-omics Models for Early Nasopharyngeal Carcinoma Screening: CfDNA Methylation, EBV DNA, and Serological Double-antibodies Detection
Led by First Affiliated Hospital, Sun Yat-Sen University · Updated on 2025-01-08
700
Participants Needed
1
Research Sites
131 weeks
Total Duration
On this page
Sponsors
F
First Affiliated Hospital, Sun Yat-Sen University
Lead Sponsor
F
First Affiliated Hospital of Fujian Medical University
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study focus on nasopharyngeal carcinoma, a cancer type with Chinese characteristics, analyze the early screening detection performance of nasopharyngeal carcinoma in the multi-cancer early screening model, and compare the performance differences among multi-omics models such as nasopharyngeal carcinoma-specific DNA methylation and fragmentome in the multi-cancer early screening model and the clinically routinely conducted Epstein-Barr virus (EBV) nucleic acid quantification (EBV DNA) test and serological double antibody (double antibodies of EBNA1-IgA and VCA-IgA) test. It suggests that compared with EBV DNA quantification and double antibody tests, in patients with nasopharyngeal carcinoma, multi-omics models such as DNA methylation can avoid false negatives, improve sensitivity, and increase the detection rate of early-stage nasopharyngeal carcinoma; in patients without nasopharyngeal carcinoma, multi-omics models such as DNA methylation can avoid false positives, improve specificity, and avoid unnecessary over-diagnosis.
CONDITIONS
Official Title
Comparison of Multi-omics Models for Early Nasopharyngeal Carcinoma Screening: CfDNA Methylation, EBV DNA, and Serological Double-antibodies Detection
Who Can Participate
Eligibility Criteria
You may qualify if you...
- 40 to 74 years old
- Clinically and/or pathologically diagnosed cancer (case arm only)
- No prior or ongoing systemic or local antitumor therapy
- Able to provide written informed consent and comply with study procedures
- Without confirmed cancer diagnosis (control arm only)
You will not qualify if you...
- Pregnant or lactating women
- Prior or current diagnosis of other malignancies
- Severe acute infection or fever (≥ 38.5 °C) within 14 days prior to screening
- Organ transplant or prior bone marrow/stem cell transplant recipients
- Blood transfusion within 30 days prior to screening
- Therapy with antibiotics, glucocorticoids, or certain drugs within 14 days prior to screening
- Unsuitable for the trial as determined by researchers
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The First Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China, 510000
Actively Recruiting
Research Team
W
WeiPing Wen
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here